Table 1. List of differentially expressed genes in leukemic LGLs compared with activated enriched CD8+ cells that belong to GO category apoptosis (GO:0006915)

Table 2b. List of 16 miRNAs showing down regulated expression levels between leukaemia samples and normal bone marrow

Table 2a. List of 17 miRNAs showing up regulated expression levels between leukaemia samples and normal bone marrow

SuppTable2 Configuration of the 48 custom TaqMan Low Density Array (LDA) platform.

SuppTable1 Configuration of the 96 custom TaqMan Low Density Array (LDA) platform

Table 2. Genes differentially expressed in two groups of anti–MAGE-3.A1 CTL clones

Table 1: Significantly altered genes with greater than 2.0-fold variation

Table S1. Selected genes that are differentially expressed between days 6 and 11 of culture

Table 1. Selected genes that are differentially expressed between In(Lu) and control cells

Table S2. Selected genes that are differentially expressed between In(Lu) and control cells at day 4 of culture

75 -gene signature that discriminated Invasive lobular v invasive ductal breast cancer

Table S2. The top 200 significant genes from the comparison of BRCA1 Missense vs BRCAX without an LCS

Table S3. The top 200 significant genes from the comparison of BRCA1 Truncating vs BRCAX without an LCS

Table S4. The top 200 significant genes from the comparison of BRCA2 Missense vs BRCAX without an LCS

Full annotated gene list of probe clusters (pclust) used in final classifier and global model

Table 3. Discordant gene expression after SOX4 RNA knockdown in Mahlavu and HuH7 cells

Supplementary Table 1  Genes with higher expressions in T3 HCC samples (the T3 > T1 group)

Table 4 Genes modulated by toremifene treatment in non-responder patients. RNA taken from women aged 65 years or older with operable or locally advanced ER-positive (ER+) breast cancer who were given pre-operative anti-estrogen toremifene. Downregulated genes

Table 4 Genes modulated by toremifene treatment in non-responder patients. RNA taken from women aged 65 years or older with operable or locally advanced ER-positive (ER+) breast cancer who were given pre-operative anti-estrogen toremifene. Upregulated genes